201st ENMC International Workshop: Autophagy in muscular dystrophies - Translational approach, 1-3 November 2013, Bussum, The Netherlands

Neuromuscular Disorders

Volumn 24, Issue 6, 2014, Pages 546-561

  Merlini, Luciano ^a   Nishino, Ichizo ^b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 6; SIALIC ACID; VALOSIN CONTAINING PROTEIN;

ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL VACUOLE; CENTRONUCLEAR MYOPATHY; CHAPERONE-MEDIATED AUTOPHAGY; CLINICAL TRIAL (TOPIC); CONGENITAL MUSCULAR DYSTROPHY TYPE 1A; DANON DISEASE; DUCHENNE MUSCULAR DYSTROPHY; FRONTOTEMPORAL DEMENTIA; GENE; GENE EXPRESSION; GLYCOGEN STORAGE DISEASE TYPE 2; GNE GENE; HUMAN; INCLUSION BODY MYOPATHY 2; LAMINOPATHY; LIMB GIRDLE MUSCULAR DYSTROPHY; MEGACONIAL TYPE CONGENITAL MUSCULAR DYSTROPHY; MUSCULAR DYSTROPHY; MYOFIBRILLAR MYOPATHY; MYOPATHY; NONHUMAN; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PAGET BONE DISEASE; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEOMICS; SKELETAL MUSCLE; SUPPLEMENTATION; SYSTEMIC DISEASE; VICI SYNDROME; X LINKED MYOPATHY WITH EXCESSIVE AUTOPHAGY; ANIMAL; ENZYMOLOGY; GENETICS; MUSCULAR DYSTROPHIES; NETHERLANDS; PATHOPHYSIOLOGY; TRANSLATIONAL RESEARCH;

ANIMALS; AUTOPHAGY; HUMANS; MUSCULAR DYSTROPHIES; NETHERLANDS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84901003315     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2014.03.009     Document Type: Article

References (77)

1. Yang Z., Klionsky D.J. Eaten alive: a history of macroautophagy. Nat Cell Biol 2010, 12:814-822.
2. Mehrpour M., Esclatine A., Beau I., Codogno P. Autophagy in health and disease 1. Regulation and significance of autophagy: an overview. Am J Physiol Cell Physiol 2013, 298:C776-C785.
3. Hamasaki M., Furuta N., Matsuda A., et al. Autophagosomes form at ER-mitochondria contact sites. Nature 2013, 495:389-393.
4. Rubinsztein D.C., Shpilka T., Elazar Z. Mechanisms of autophagosome biogenesis. Curr Biol 2012, 22:29-34.
5. Wirth M., Joachim J., Tooze S.A. Autophagosome formation - the role of ULK1 and Beclin1-PI3KC3 complexes in setting the stage. Semin Cancer Biol 2013, 23:301-309.
6. Orsi A., Razi M., Dooley H.C., et al. Dynamic and transient interactions of Atg9 with autophagosomes, but not membrane integration, are required for autophagy. Mol Biol Cell 2012, 23:1860-1873.
7. Ulbricht A., Eppler F.J., Tapia V.E., et al. Cellular mechanotransduction relies on tension-induced and chaperone-assisted autophagy. Curr Biol 2013, 23:430-435.
8. Sandri M. Autophagy in skeletal muscle. FEBS Lett 2010, 584:1411-1416.
9. Romanello V., Guadagnin E., Gomes L., et al. Mitochondrial fission and remodelling contributes to muscle atrophy. EMBO J 2010, 29:1774-1785.
10. Lokireddy S., Wijesoma I.W., Teng S., et al. The ubiquitin ligase mul1 induces mitophagy in skeletal muscle in response to muscle-wasting stimuli. Cell Metab 2012, 16:613-624.
11. Grumati P., Coletto L., Sabatelli P., et al. Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration. Nat Med 2010, 16:1313-1320.
12. Kim K.H., Jeong Y.T., Oh H., et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med 2013, 19:83-92.
13. Moresi V., Carrer M., Grueter C.E., et al. Histone deacetylases 1 and 2 regulate autophagy flux and skeletal muscle homeostasis in mice. Proc Natl Acad Sci U S A 2012, 109:1649-1654.
14. Grumati P., Coletto L., Schiavinato A., et al. Physical exercise stimulates autophagy in normal skeletal muscles but is detrimental for collagen VI-deficient muscles. Autophagy 2011, 7:1415-1423.
15. Jamart C., Francaux M., Millet G.Y., Deldicque L., Frere D., Feasson L. Modulation of autophagy and ubiquitin-proteasome pathways during ultra-endurance running. J Appl Physiol 2012, 112:1529-1537.
16. He C., Bassik M.C., Moresi V., et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 2012, 481:511-515.
17. Arndt V., Dick N., Tawo R., et al. Chaperone-assisted selective autophagy is essential for muscle maintenance. Curr Biol 2010, 20:143-148.
18. Nascimbeni A.C., Fanin M., Masiero E., Angelini C., Sandri M. Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients. Autophagy 2012, 8:1697-1700.
19. Bonaldo P., Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Models Mech 2013, 6:25-39.
20. Tsuyuki S., Takabayashi M., Kawazu M., et al. Detection of mRNA as an indicator of autophagosome formation. Autophagy 2013, 10:497-513.
21. Sandri M. Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int J Biochem Cell Biol 2013, 45:2121-2129.
22. Feldkirchner S., Walter M.C., Muller S., et al. Proteomic characterization of aggregate components in an intrafamilial variable FHL1-associated myopathy. Neuromuscul Disord 2013, 23:418-426.
23. Raben N., Wong A., Ralston E., Myerowitz R. Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet C Semin Med Genet 2012, 160:13-21.
24. Spampanato C., Feeney E., Li L., et al. Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO Mol Med 2013, 5:691-706.
25. Raben N., Schreiner C., Baum R., et al. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder-murine Pompe disease. Autophagy 2010, 6:1078-1089.
26. Masiero E., Sandri M. Autophagy inhibition induces atrophy and myopathy in adult skeletal muscles. Autophagy 2010, 6:307-309.
27. Medina D.L., Fraldi A., Bouche V., et al. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev Cell 2011, 21:421-430.
28. Settembre C., Ballabio A. TFEB regulates autophagy: an integrated coordination of cellular degradation and recycling processes. Autophagy 2011, 7:1379-1381.
29. Nishino I. Autophagic vacuolar myopathies. Curr Neurol Neurosci Rep 2003, 3:64-69.
30. Kim H., Cho A., Lim B.C., et al. A 13-year-old girl with proximal weakness and hypertrophic cardiomyopathy with Danon disease. Muscle Nerve 2010, 41:879-882.
31. Ramachandran N., Munteanu I., Wang P., et al. VMA21 deficiency prevents vacuolar ATPase assembly and causes autophagic vacuolar myopathy. Acta Neuropathol 2013, 125:439-457.
32. Bertrand A.T., Chikhaoui K., Yaou R.B., Bonne G. Clinical and genetic heterogeneity in laminopathies. Biochem Soc Trans 2011, 39:1687-1692.
33. Park Y.E., Hayashi Y.K., Bonne G., et al. Autophagic degradation of nuclear components in mammalian cells. Autophagy 2009, 5:795-804.
34. Ramos F.J., Chen S.C., Garelick M.G., et al. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med 2012, 4:144ra103.
35. Choi J.C., Muchir A., Wu W., et al. Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation. Sci Transl Med 2012, 4:144ra102.
36. Cattin M.E., Bertrand A.T., Schlossarek S., et al. Heterozygous LmnadelK32 mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicity. Hum Mol Genet 2013, 22:3152-3164.
37. Cho A., Hayashi Y.K., Monma K., et al. Mutation profile of the GNE gene in Japanese patients with distal myopathy with rimmed vacuoles (GNE myopathy). J Neurol Neurosurg Psychiatry 2013, 10.1136/jnnp-2013-305587.
38. Eisenberg I., Avidan N., Potikha T., et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001, 29:83-87.
39. Malicdan M.C., Noguchi S., Nonaka I., Hayashi Y.K., Nishino I. A Gne knockout mouse expressing human GNE D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. Hum Mol Genet 2007, 16:2669-2682.
40. Jungbluth H., Wallgren-Pettersson C., Laporte J.F. 198th ENMC International Workshop: 7th Workshop on Centronuclear (Myotubular) myopathies, 31st May - 2nd June 2013, Naarden, The Netherlands. Neuromuscul Disord 2013, 23:1033-1043.
41. Durieux A.C., Vassilopoulos S., Laine J., et al. A centronuclear myopathy-dynamin 2 mutation impairs autophagy in mice. Traffic 2012, 13:869-879.
42. Dowling J.J., Low S.E., Busta A.S., Feldman E.L. Zebrafish MTMR14 is required for excitation-contraction coupling, developmental motor function and the regulation of autophagy. Human Mol Genet 2010, 19:2668-2681.
43. Fetalvero K.M., Yu Y., Goetschkes M., et al. Defective autophagy and mTORC1 signaling in myotubularin null mice. Mol Cell Biol 2013, 33:98-110.
44. Al-Qusairi L., Prokic I., Amoasii L., et al. Lack of myotubularin (MTM1) leads to muscle hypotrophy through unbalanced regulation of the autophagy and ubiquitin-proteasome pathways. FASEB 2013, 27:3384-3394.
45. Kley R.A., van der Ven P.F., Olive M., et al. Impairment of protein degradation in myofibrillar myopathy caused by FLNC/filamin C mutations. Autophagy 2013, 9:422-423.
46. Kley R.A., Maerkens A., Leber Y., et al. A combined laser microdissection and mass spectrometry approach reveals new disease relevant proteins accumulating in aggregates of filaminopathy patients. Mol Cell Proteomics 2013, 12:215-227.
47. Sarparanta J., Jonson P.H., Golzio C., et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. Nat Genet 2012, 44(450-5):S1-S2.
48. Raz V., Butler-Browne G., van Engelen B., Brais B. 191st ENMC International Workshop: recent advances in oculopharyngeal muscular dystrophy research: From bench to bedside 8-10 June 2012, Naarden, The Netherlands. Neuromuscul Disord 2013, 23:516-523.
49. Simonelig M. PABPN1 shuts down alternative poly(A) sites. Cell Res 2012, 22:1419-1421.
50. de Klerk E., Venema A., Anvar S.Y., et al. Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation. Nucleic Acids Res 2012, 40:9089-9101.
51. Jenal M., Elkon R., Loayza-Puch F., et al. The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. Cell 2012, 149:538-553.
52. Anvar S.Y., Raz Y., Verway N., et al. A decline in PABPN1 induces progressive muscle weakness in Oculopharyngeal muscle dystrophy and in muscle aging. Aging (Albany NY) 2013, 5:412-426.
53. Udd B. Distal myopathies-new genetic entities expand diagnostic challenge. Neuromuscul Disord 2012, 22:5-12.
54. Hackman P., Sarparanta J., Lehtinen S., et al. Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1. Ann Neurol 2012, 10.1002/ana.23831.
55. Ju J.S., Fuentealba R.A., Miller S.E., et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol 2009, 187:875-888.
56. Ritz D., Vuk M., Kirchner P., et al. Endolysosomal sorting of ubiquitylated caveolin-1 is regulated by VCP and UBXD1 and impaired by VCP disease mutations. Nat Cell Biol 2011, 13:1116-1123.
57. Ching J.K., Elizabeth S.V., Ju J.S., Lusk C., Pittman S.K., Weihl C.C. MTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy. Hum Mol Genet 2013, 22:1167-1179.
58. Cullup T., Kho A.L., Dionisi-Vici C., et al. Recessive mutations in EPG5 cause Vici syndrome, a multisystem disorder with defective autophagy. Nat Gen 2013, 45:83-87.
59. McClelland V., Cullup T., Bodi I., et al. Vici syndrome associated with sensorineural hearing loss and evidence of neuromuscular involvement on muscle biopsy. Am J Med Genet A 2010, 152A:741-747.
60. Zou Y., Zhang R.Z., Sabatelli P., Chu M.L., Bonnemann C.G. Muscle interstitial fibroblasts are the main source of collagen VI synthesis in skeletal muscle: implications for congenital muscular dystrophy types Ullrich and Bethlem. J Neuropathol Exp Neurol 2008, 67:144-154.
61. Allamand V., Merlini L., Bushby K. Consortium for Collagen VIRM. 166th ENMC International Workshop on Collagen type VI-related Myopathies, 22-24 Naarden, The Netherlands. Neuromuscul Disord 2009, 2010(20):346-354.
62. Angelin A., Tiepolo T., Sabatelli P., et al. Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins. Proc Natl Acad Sci U S A 2007, 104:991-996.
63. Merlini L., Angelin A., Tiepolo T., et al. Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proc Natl Acad Sci U S A 2008, 105:5225-5229.
64. Carmignac V., Svensson M., Korner Z., et al. Autophagy is increased in laminin alpha2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A. Hum Mol Genet 2011, 20:4891-4902.
65. Gawlik K.I., Durbeej M. Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies. Skelet Muscle 2011, 1:9.
66. Mitsuhashi S., Ohkuma A., Talim B., et al. A congenital muscular dystrophy with mitochondrial structural abnormalities caused by defective de novo phosphatidylcholine biosynthesis. Am J Hum Genet 2011, 88:845-851.
67. Mitsuhashi S., Hatakeyama H., Karahashi M., et al. Muscle choline kinase beta defect causes mitochondrial dysfunction and increased mitophagy. Hum Mol Genet 2011, 20:3841-3851.
68. Pauly M., Daussin F., Burelle Y., et al. AMPK activation stimulates autophagy and ameliorates muscular dystrophy in the mdx mouse diaphragm. Am J Pathol 2012, 181:583-592.
69. De Palma C., Morisi F., Cheli S., et al. Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis 2012, 3:e418.
70. Hindi S.M., Sato S., Choi Y., Kumar A. Distinct roles of TRAF6 at early and late stages of muscle pathology in the mdx model of Duchenne muscular dystrophy. Hum Mol Genet 2013, 23:1492-1505.
71. Rubinsztein D.C., Codogno P., Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 2012, 11:709-730.
72. Merlini L., Bernardi P. Therapy of collagen VI-related myopathies (Bethlem and Ullrich). Neurotherapeutics 2008, 5:613-618.
73. Merlini L., Sabatelli P., Armaroli A., et al. Cyclosporine A in Ullrich congenital muscular dystrophy: long-term results. Oxid Med Cell Longev 2011, 2011:139194.
74. Miscione M.T., Bruno F., Ripamonti C., et al. Body composition, muscle strength, and physical function of patients with Bethlem myopathy and Ullrich congenital muscular dystrophy. Sci World J 2013, 2013:152684.
75. Malicdan M.C., Noguchi S., Hayashi Y.K., Nonaka I., Nishino I. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. Nat Med 2009, 15:690-695.
76. Pellegrini C., Zulian A., Gualandi F., et al. Melanocytes-a novel tool to study mitochondrial dysfunction in Duchenne muscular dystrophy. J Cell Physiol 2013, 228:1323-1331.
77. Klionsky D.J., Abdalla F.C., Abeliovich H., et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012, 8:445-544.